Drugs / SC10914
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02940132 | Oct 2016 → Mar 2018 | cancer | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04486937 | Aug 2020 → Dec 2021 | castration-resistant prostate carcinoma | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04556539 | Dec 2020 → Dec 2021 | ovarian cancer | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04556292 | Aug 2020 → Mar 2022 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast carcinoma | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sc10914 | “The subjects oral administration sc10914 tablets 400mg on an empty stomach, three times a day, for 28 consecutive days as a treatment cycle” NCT04486937 ↗4“SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation” NCT04486937 ↗ |
| Action | Inhibit | “SC10914 is a potent selective PARP-1 and PARP-2 inhibitor.” NCT02940132 ↗ |
| Route | Oral | “SC10914 will be administered orally.” NCT02940132 ↗ |